We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

Myers Squibb Company, Johnson & Johnson, Bausch Health Companies Inc, AbbVie Inc. Read 's Market Analysis on Investing.com ...

Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

The remaining 20% is their coinsurance. S-ketamine, or esketamine (Spravato), is an FDA-approved nasal spray that doctors and healthcare professionals may prescribe for major depressive disorder ...

The 2019 winner of "RuPaul's Drag Race UK," who died in January, had experienced cardiac arrest following ketamine use, The ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly given its recent $14.6 billion acquisition of Intra-Cellular Therapeutics and ...

A DMT-based treatment for people with treatment-resistant depression (TRD) has entered Phase 2 clinical trials.